Articles tagged "Liver transplantation"

2016 American Transplant Congress
The Finances of Broader Sharing of Livers Following Share 35.
A. Harper,¹ E. Edwards,¹ R. Gilroy,² W. Chapman,³ D. Mulligan,⁴ G. Klintmalm.⁵
¹Research, UNOS, Richmond, VA; ²Univ.of Kansas Med Ctr, Kansas City, KS; ³Washington Univ, St Louis, MO; ⁴Yale Med Ctr, New Haven, CT; ⁵Baylor Univ, Houston, TX.
Background. After implementation of the “Share 35” policy in 2013, many centers and OPOs reported increased costs associated with broader sharing. The OPTN Liver and…
2016 American Transplant Congress
Pre-Transplant Loco-Regional Therapy for Hepatocellular Carcinoma and Post-Transplant Outcomes: A National Study.
M. Nazzal,¹ J. Chen,¹ K. Lentine,¹ M. Schnitzler,¹ J. Tuttle-Newhall,² C. Varma,¹ A. Taha,¹ A. Said,¹ H. Xiao,¹ H. Randall.¹
¹Saint Louis Univ, Saint Louis; ²East Carolina Univ, Greenville.
Currently most transplant centers use loco-regional therapy to bridge liver transplant (LT) candidates with hepatocellular carcinoma (HCC). However, limited data are available to support the…
2016 American Transplant Congress
Hospitalizations for Cardiovascular Disease After Liver Transplantation in the United States: Epidemiology, Outcomes, and Costs.
A. Mathur, Y.-H. Chang, D. Steidley, N. Khurmi, N. Katariya, A. Singer, W. Hewitt, K. Reddy, A. Moss.
Transplant Center, Mayo Clinic, Phoenix.
Background: Cardiovascular disease (CVD) is a leading cause of post-liver transplant death, and variable care patterns may affect outcomes. We aimed to describe epidemiology, outcomes,…
2016 American Transplant Congress
Serelaxin Decreases the Severity of Cold Ischemia-Reperfusion Injury After Liver Transplantation in Mice.
S. Kageyama, K. Nakamura, R. Busuttil, J. Kupiec-Weglinski.
The Dumont-UCLA Transplantation Center, UCLA, Los Angeles, CA.
Background. Extended cold preservation contributes to ischemia-reperfusion injury (IRI), which impairs graft function and leads to poor clinical outcomes. Serelaxin (SER), a recombinant form of…
2016 American Transplant Congress
Large Single-Center Experience of Sofosbuvir and Ledipasvir Therapy for the Treatment of Post-Liver Transplant Patients with Hepatitis C Virus.
J. Wedd, R. Ford, J. Norvell, S. Parekh, N. Cheng, N. Young, A. Patel, R. Maheshwari, R. Vora, O. Mgbemena, J. Spivey, A. Pillai.
Medicine, Emory University, Atlanta, GA.
Background/Aims: Controlled trials of direct acting antiviral therapy for Hepatitis C Virus (HCV) show impressive sustained virologic response (SVR) rates, but post-transplant data of sofosbuvir…
2016 American Transplant Congress
Portal Vein Complication After Living Donor Right Hepatectomy.
D.-H. Jung, S.-G. Lee, S. Hwang, K.-H. Kim, C.-S. Ahn, D.-B. Moon, T.-Y. Ha, G.-W. Song, W.-J. Kim, S.-H. Kim, W.-H. Kang, J.-H. Kwon, E.-K. Jwa, H.-D. Cho.
Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
BackgroundLiving donor hepatectomy may carry a significant risk of morbidity and mortality for the otherwise healthy donor. Portal vein (PV) complication after donor hepatectomy is…
2016 American Transplant Congress
Effect of Modifying Life Support Withdrawal Practices on Outcomes of Donation After Circulatory Death in Liver Transplantation: A Meta-Analysis.
Y. Cao,^1,2 S. Shahrestani,³ H. Chew,^2,4 M. Crawford,⁵ P. Macdonald,^1,2,4 J. Laurence,^3,5,7 W. Hawthorne,^3,6 K. Dhital,^1,2,4 H. Pleass.^3,5,6
¹Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia; ²Victor Chang Cardiac Research Institute, Sydney, NSW, Australia; ³Sydney Medical School, University of Sydney, Sydney, NSW, Australia; ⁴Cardiac Transplant Unit, St. Vincent's Hospital, Sydney, NSW, Australia; ⁵Australian National Liver Transplant Unit, Royal Prince Alfred Hospital, Sydney, NSW, Australia; ⁶The Department of Surgery, Westmead Hospital, Sydney, NSW, Australia; ⁷Institute of Academic Surgery, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
Aim. Donor warm ischaemic time is identified as the main risk factor for poor outcomes in liver transplantation using donation after circulatory death (DCD) compared…
2016 American Transplant Congress
The Impact of Gender Discordance on Graft Survival Among Liver Transplant Recipients.
J. Moore, X. Luo, A. Massie, T. Purnell, D. Mogul, D. Segev.
Johns Hopkins School of Medicine, Baltimore.
Past studies have shown inferior liver graft survival in gender-discordant recipient/donor pairings compared to gender-matched pairings, particularly in male recipients of female donor livers. However,…
2016 American Transplant Congress
LACE Index Risk Assessment Tool Predicts Liver Transplant Readmissions.
A. Masoumi,¹ R. Barth,² J. LaMattina,² D. Bruno,² L. Hebert,¹ N. Schluterman,³ S. Hanish.²
¹University of Maryland Medical Center, Baltimore, MD; ²Department of Surgery, University of Maryland School of Medicine, Baltimore, MD; ³Department of Epidemiology, University of Maryland School of Public Health, Baltimore, MD.
Background:One-fifth of Medicare patients are readmitted to the hospital an annual cost of $17.4 billion. The LACE Index (Length of stay, Acuity of the admission,…
2016 American Transplant Congress
Outcomes of Arterial and Venous Conduits for Vessel Reconstruction in Liver Transplantation.
J. Tan,¹ G. Oniscu.²
¹University of Edinburgh, Edinburgh, United Kingdom; ²Liver Transplant Unit, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.
Background: The use of hepatic artery (HA) and portal vein (PV) conduits is a recognised alternative technique in vessel reconstruction during liver transplantation. The hepatic…